{
    "clinical_study": {
        "@rank": "65410", 
        "arm_group": {
            "arm_group_label": "Melanoma vaccine", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study is based on the hypothesis that stimulation of the immune response against the\n      tumor can help destroy residual tumor in melanoma patients with very high risk for disease\n      recurrence and in patients with relatively low tumor burden who already got first line\n      treatment for their disease.\n\n      Ongoing clinical trials in the Hadassah Hospital have shown that vaccination of patients\n      with a cell line of tumor cells from the patient himself, or with a combination of three\n      cell lines that partially match the patient's cell characteristics, could improve the immune\n      response against the tumor, was associated with improved disease-free and overall survival.\n\n      In this study, the investigators will evaluate the efficacy of a modified tumor cell\n      vaccine, in terms of immune response,improved disease-free and overall survival. The vaccine\n       consists of a cell line that has a high expression level of melanoma molecules, and has\n      been genetically modified to induce a strong immune response."
        }, 
        "brief_title": "Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients", 
        "condition": [
            "High Risk HLA-A2+ Melanoma", 
            "Metastatic Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Melanoma", 
                "Neoplasm Metastasis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients included in this protocol must carry one or more of the following tissue\n             typing alleles:  HLA-A2, -A24, -A33, -B35, -B49, -CW04/12(04/08). We estimate that\n             50% of melanoma patients will be eligible.\n\n          2. Cutaneous malignant melanoma AJCC stage IIb (over 4 mm) or IIc (ulcerated melanoma\n             over 4mm).\n\n          3. Metastatic melanoma AJCC stage III (nodal involvement, N1-3a,b) post surgical removal\n             of lymph nodes.\n\n          4. Metastatic melanoma AJCC stage IV, completely resected.\n\n          5. Non cutaneous malignant melanoma of respective stages including uveal and mucosal\n             melanoma.\n\n          6. Melanoma can be of either mutant or wild-type B-RAF.\n\n          7. Karnofsky performance status over 80 (Normal activity with effort).\n\n          8. No active cardio-respiratory disease.\n\n          9. Hematocrit over 25% and WBC over 3000.\n\n         10. Informed consent of the patient.\n\n        Exclusion Criteria:\n\n          1. Administration of cytotoxic drugs or extensive radiotherapy less than 28 days prior\n             to protocol administration.\n\n          2. Active brain metastases requiring cortico-steroids.\n\n          3. Concurrent malignancy (other than skin cancer, carcinoma in situ of cervix and early\n             stage prostate cancer).\n\n          4. Active serious infection.\n\n          5. Allergy to penicillin.\n\n          6. Patient's wish to withdraw from the study at any stage."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01861938", 
            "org_study_id": "0419-12-HMO"
        }, 
        "intervention": {
            "arm_group_label": "Melanoma vaccine", 
            "intervention_name": "Melanoma vaccine modified to express HLA A2/4-1BB ligand", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "melanoma", 
            "vaccine", 
            "Resectable AJCC stage IV", 
            "AJCC stages IIb-c, III", 
            "Patients with low-burden", 
            "failed", 
            "respond", 
            "one treatment line"
        ], 
        "lastchanged_date": "May 23, 2013", 
        "number_of_arms": "1", 
        "official_title": "Allogeneic Vaccine Modified to Express HLA A2/4-1BB Ligand for High Risk or Low Residual Disease Melanoma Patients", 
        "other_outcome": {
            "measure": "Emergence of anti-tumor T cell reactivity", 
            "safety_issue": "No", 
            "time_frame": "To be measured one month after the last vaccine was admininstered, on average 18-20 weeks after treatment start"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Israel Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of adverse effects", 
            "safety_issue": "Yes", 
            "time_frame": "For 20 weeks from the start of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01861938"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Overall and disease free survival", 
            "safety_issue": "No", 
            "time_frame": "For at least five years"
        }, 
        "source": "Hadassah Medical Organization", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hadassah Medical Organization", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}